Malignant transformation of human skin fibroblasts by two alternative pathways

Advances in Experimental Medicine and Biology

Volumn 720, Issue , 2011, Pages 191-207

  McCormick, J Justin ^a,b   Maher, Veronica M ^a,b  

^a Michigan State University ^*  (United States)

^b Michigan State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; FIBULIN; FIBULIN 1D; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 12; MESSENGER RNA; OXYGEN; PROTEIN CDC42; PROTEIN TYROSINE KINASE; RAC1 PROTEIN; RAS PROTEIN; SPROUTY 2 PROTEIN; SPROUTY PROTEIN; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; UNCLASSIFIED DRUG; UROKINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; H RAS PROTEIN; N RAS PROTEIN; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR B; PROTEIN KINASE FES; PROTEIN P53; SCATTER FACTOR RECEPTOR;

CARCINOGENESIS; CELL SURVIVAL; CONFERENCE PAPER; DNA DAMAGE; EFFECTOR CELL; EPIGENETICS; FIBROBLAST CULTURE; FIBROMA; FIBULIN 1D GENE; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INACTIVATION; GENE OVEREXPRESSION; GENETIC IDENTIFICATION; GENETIC TRANSFECTION; HUMAN; INTRACELLULAR SIGNALING; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN GENE; MALIGNANT TRANSFORMATION; MET GENE; NONHUMAN; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE MYC; ONCOGENE N RAS; OXIDATIVE STRESS; OXYGEN CONCENTRATION; P14ARF GENE; P16IKNA GENE; PDGF B GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPROUTY 2 GENE; TUMOR SUPPRESSOR GENE; ARTICLE; GENE ACTIVATION; GENE EXPRESSION; LIFESPAN; LOSS OF FUNCTION MUTATION; ONCOGENE; PROTEIN DEPLETION; PROTEIN KINASE FES GENE; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; ANIMAL; CELL CULTURE; CELL TRANSFORMATION; FIBROBLAST; PATHOLOGY; PHYSIOLOGY; REVIEW; SKIN;

MUS;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; FIBROBLASTS; HUMANS; RAS PROTEINS; SIGNAL TRANSDUCTION; SKIN; SRC-FAMILY KINASES; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80053908435     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0254-1_16     Document Type: Conference Paper

References (72)

1. Earle WR (1943) Production of malignancy in vitro IV. The mouse fibroblast cultures and changes seen in living cells. J Natl Cancer Inst 4:165-212
2. Roussos ET, Keckesova Z, Haley JD, Epstein DM, Weinberg RA, Condeelis JS (2010) AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Res 70: 7360-7364
3. Earle WR, Nettleship A, Schilling EL, Stark TH, Straus NR, Brown MF, Shelton E (1943) Production of malignancy in vitro V. Results of injections of cultures into mice. J Natl Cancer Inst 4:213-227
4. McCormick JJ, Maher VM (1988) Towards an understanding of the malignant transformation of diploid human fibroblasts. Mutat Res 199:273-291
5. Namba M, Nishitani K, Fukushima F, Kimoto T, Utsunomiya J, Hayflick L (1981) Neoplastic transformation of human diploid fibroblasts treated with chemical carcinogens and Co-60 Y-rays. Gann Monogr Cancer Res 27:221-230
6. Namba M, Nishitani K, Hyodoh F, Fukushima F, Kimoto T (1985) Neoplastic transformation of human diploid fibroblasts (KMST-6) by treatment with Co-60 gamma rays. Int J Cancer 35:275-280 (Pubitemid 16179973)
7. Yoshii H, Watanabe M (2009) Intervention of oxygencontrol ability to radiation sensitivity, cell aging and cell transformation. J Radiat Res (Tokyo) 50:127-137
8. Drayton S, Peters G (2002) Immortalisation and transformation revisited. Curr Opin Genet Dev 12:98-104.Review (Pubitemid 34094997)
9. Drayton S, Brookes S, Rowe J, Peters G (2004) The significance of p16INK4a in cell defenses against transformation. Cell Cycle 3:611-615. Review (Pubitemid 40278203)
10. Kendall SD, Adam SJ, Counter CM (2006) Genetically engineered human cancer models utilizing mammalian transgene expression. Cell Cycle 5:1074-1079 (Pubitemid 43778735)
11. Morgan TL, Yang D, Fry DG, Hurlin PJ, Kohler SK, Maher VM, McCormick JJ (1991) Characteristics of an infinite life span diploid human fibroblast cell strain and a near-diploid strain arising from a clone of cells expressing a transfected v-myc oncogene. Exp Cell Res 197:125-136
12. Land H, Chen AC, Morgenstern JP, Parada LF, Weinberg RA (1986) Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts. Mol Cell Biol 6:1917-1925
13. Gallego Melcón S, Sánchez de Toledo Codina J (2007) Molecular biology of rhabdomyosarcoma. Clin Transl Oncol 9:415-419. Review
14. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, Inoue M (1999) Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 59:551-557 (Pubitemid 29076049)
15. Wang Q, Maher VM, McCormick JJ (1993) Telomerase activity in human fibroblasts correlates with the rate of cell growth, not with the rate of changes in telomere length. Proceedings-International Symposium on Molecular Mechanisms of Radiation and Chemical Carcinogen-Induced Cell Transformation, sponsored by the Department of Energy and the Commission of European Communities, Mackinac Island, MI, Sep. 19-23, Abstract #26
16. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, Ariga H, Inoue M (2000) Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 28:669-677 (Pubitemid 30068249)
17. Lou Z, Maher VM, McCormick JJ (2005) Identification of the promoter of human transcription factor Sp3 and characterization of the role of Sp1 and Sp3 in the expression of Sp3 protein. Gene 351:51-59 (Pubitemid 40732619)
18. Tao L, Dong Z, Zannis-Hadjopoulos M, Price GB (2001) Immortalization of human WI38 cells is associated with differential activation of the c-myc origins. J Cell Biochem 82:522-534 (Pubitemid 32729415)
19. Casillas MA, Brotherton SL, Andrews LG, Ruppert JM, Tollefsbol TO (2003) Induction of endogenous telomerase (hTERT) by c-Myc in WI-38 fibroblasts transformed with specific genetic elements. Gene 316:57-65 (Pubitemid 37249353)
20. Andeol Y, Nardeux PC, Daya-Grosjean L, Brison O, Debrian J, Suarez H (1988) Both N-ras and c-myc are activated in the SHAC human stomach fibrosarcoma cell line. Int J Cancer 41:732-737
21. Missiaglia E, Selfe J, Hamdi M, Williamson D, Schaaf G, Fang C, Koster J, Summersgill B, Messahel B, Versteeg R, Pritchard-Jones K, Kool M, Shipley J (2009) Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development. Genes Chromosomes Cancer 48:455-467
22. Tsiatis AC, Herceg ME, Keedy VL, Halpern JL, Holt GE, Schwartz HS, Cates JM (2009) Prognostic significance of c-Myc expression in soft tissue leiomyosarcoma. Mod Pathol 22:1432-1438
23. Taggie-Hoffman A, McCormick JJ (1999) Decreased p16INK4a expression in tumorigenic fibroblastic cell lines derived from MSU-1.1 cells [unpublished studies]
24. Ozenne P, Eymin B, Brambilla E, Gazzeri S (2010) The ARF tumor suppressor: structure, functions and status in cancer. Int J Cancer 127:2239-2247. Review
25. Voorhoeve PM, Agami R (2003) The tumor-suppressive functions of the human INK4a locus. Cancer Cell 4:311-319 (Pubitemid 37329795)
26. Weihrauch M, Markwarth A, Lehnert G, Wittekind C, Wrbitzky R, Tannapfel A (2002) Abnormalities of the ARF-p53 pathway in primary angiosarcomas of the liver. Hum Pathol 33:884-892
27. Obana K, Yang HW, Piao HY, Taki T, Hashizume K, Hanada R, Yamamoto K, Tanaka Y, Toyoda Y, Takita J, Tsuchida Y, Hayashi Y (2003) Aberrations of p16INK4A, p14ARF and p15INK4B genes in pediatric solid tumors. Int J Oncol 23:1151-1157
28. Brown R, Marshall CJ, Pennie SG, Hall A (1984) Mechanism of activation of an N-ras gene in the human fibrosarcoma cell line HT1080. EMBO J 3:1321-1326
29. Paterson H, Reeves B, Brown R, Hall A, Furth M, Bos J, Jones P, Marshall C (1987) Activated N-ras controls the transformed phenotype of HT1080 human fibrosarcoma cells. Cell 51:803-812
30. Hamad NM, Elconin JH, Karnoub AE, Bai W, Rich JN, Abraham RT, Der, CJ, Counter CM (2002) Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 16:2045-2057. Review
31. Fry DG, Milam LD, Dillberger JE, Maher VM, McCormick JJ (1990) Malignant transformation of an infinite life span human fibroblast cell strain by transfection with v-Ki-ras. Oncogene 5:1415-1418
32. Wilson DM, Yang D, Dillberger JE, Dietrich SE, Maher VM, McCormick JJ (1990) Malignant transformation of human fibroblasts by a transfected N-ras oncogene. Cancer Res 50:5587-5593 (Pubitemid 20303023)
33. Lin C, Maher VM, McCormick JJ (1995) Malignant transformation of human fibroblast strain MSU-1.1 by v-fes requires an additional genetic change. Int J Cancer 63:140-147
34. Hurlin PJ, Maher VM, McCormick JJ (1989) Malignant transformation of human fibroblasts caused by expression of a transfected T24 HRAS oncogene. Proc Natl Acad Sci USA 86:187-191 (Pubitemid 19036352)
35. Wong-Staal F, Dalla-Favera R, Gelmann EP, Manzari V, Szala S, Josephs SF, Gallo RC (1981) The v-sis transforming gene of simian sarcoma virus is a new onc gene of primate origin. Nature 294:273-275 (Pubitemid 12221496)
36. Pantazis P, Pelicci PG, Dalla-Favera R, Antoniades HN (1985) Synthesis and secretion of proteins resembling platelet-derived growth factor by human glioblastoma and fibrosarcoma cells in culture. Proc Natl Acad Sci USA 82:2404-2408 (Pubitemid 15064496)
37. Yang D, Kohler SK, Maher VM, McCormick JJ (1994) v-sis oncogene-induced transformation of human fibroblasts into cells capable of forming benign tumors. Carcinogenesis 15:2167-2175 (Pubitemid 24317475)
38. Weiss R, Teicg N, Varmus H, Coffin J (eds) (1985) RNA tumor viruses: molecular biology of tumor viruses, 2nd ed. 2/Supplements and appendices. Cold Spring Harbor Laboratory, New York
39. Guan H, Zhou Z, Gallick GE, Jia SF, Morales J, Sood AK, Corey SJ, Kleinerman ES (2008) Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther 7:1807-1816
40. Lin C, Wang Q, Maher VM, McCormick JJ (1994) Malignant transformation of a human fibroblast cell strain by transfection of a v-fes oncogene, but not by transfection of a gag-human c-fes construct. Cell Growth Differ 5:1381-1387 (Pubitemid 24381527)
41. Reinhold DS, Walicka M, Elkassaby M, Milam LD, Kohler SK, Dunstan RW, McCormick JJ (1996) Malignant transformation of human fibroblasts by ionizing radiation. Intl J Radiat Biol 69:707-715 (Pubitemid 26248224)
42. Boley SE, McManus TP, Maher VM, McCormick JJ (2000) Malignant transformation of human fibroblast cell strain MSU-1.1 by N-methyl-N- nitrosourea: evidence of elimination of p53 by homologous recombination. Cancer Res 60:4105-4111 (Pubitemid 30636592)
43. Yang D, Louden C, Reinhold DS, Kohler SK, Maher VM, McCormick JJ (1992) Malignant transformation of human fibroblast cell strain MSU-1.1 by (+)-7b,8adihydroxy- 9a,10a-epoxy-7,8,9,10-tetrahydrobenzo[a] pyrene. Proc Natl Acad Sci USA 89:2237-2241
44. Ashraf-Khan S (1996) Malignant transformation of the human fibroblast cell strain MSU-1.1 by ultraviolet radiation: correlation of tumorigenicity with anchorage independence and growth factor independence. ProQuest, UMI Dissertations Publishing
45. O'Reilly S, Walicka M, Kohler SK, Dunstan R, Maher VM, McCormick JJ (1998) Dose-dependent transformation of MSU-1.1 human fibroblasts and characterization of the neoplastic characteristics. Radiation Res 150:577-584 (Pubitemid 28499058)
46. Schärer E, Iggo R (1992) Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res 20:1539-1545
47. McManus TP, McCormick JJ (2000) Restoration of wild-type p53 in focus-derived, tumorigenic human fibroblast strain lacking p53 expression inhibits focus formation and tumorigenicity of the cells without affecting cell growth in culture [unpublished studies]
48. Pérot G, Chibon F, Montero A, Lagarde P, de Thé H, Terrier P, Guillou L, Ranchère D, Coindre JM, Aurias A (2010) Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Am J Pathol 177:2080-2090
49. O'Reilly SA, McCormick JJ (2002) Analysis of genetic changes involved in carcinogen-induced malignant transformation of a human fibroblast cell strain in culture [unpublished studies]
50. Ortega S, Malumbres M, Barbacid M (2002) Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602:73-87 (Pubitemid 34311901)
51. Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, Karchin R, Kinzler KW, Vogelstein B, Nowak MA (2010) Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA 107:18545-18550
52. Birchmeier C, Birchmeier W, Gherardi E, VandeWoude GF (2003) MET, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925 (Pubitemid 37493640)
53. Liang H, O'Reilly S, Liu Y, Abounader R, Laterra J, Maher VM, McCormick JJ (2004) Sp1 regulates expression of MET, and ribozyme-induced downregulation of MET in fibrosarcoma-derived human cells reduces or eliminates their tumorigenicity. Int J Oncol 24:1057-1068
54. Lou Z, O'Reilly S, Liang H, Maher VM, Sleight SD, McCormick JJ (2005) Down-regulation of overexpressed Sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res 65:1007-1017 (Pubitemid 40216463)
55. Taubert H, Würl P, Greither T, Kappler M, Bache M, Lautenschläger C, Füssel S, Meye A, Eckert AW, Holzhausen HJ, Magdolen V, Kotzsch M (2010) Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients. Br J Cancer 102:731-737
56. Teng HW, Wang HW, Chen WM, Chao TC, Hsieh YY, Hsih CH, Tzeng CH, Chen PC, Yen CC (2011) Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma. J Surg Oncol 103:773-781
57. Kilvaer TK, Valkov A, Sorbye S, Smeland E, Bremnes RM, Busund LT, Donnem T (2010) Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis. PLoS One 14:e15368
58. Jankun J, Maher VM, McCormick JJ (1991) Malignant transformation of human fibroblasts correlates with increased activity of receptor-bound plasminogen activator. Cancer Res 51:1221-1226
59. Allgayer H, Heiss MM, Riesenberg R, Grutzner KU, Tarabichi A, Babic R, Schildberg FW (1997) Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Res 57:1394-1399 (Pubitemid 27152567)
60. Appledorn DM, Dao K, O'Reilly S, Maher VM, McCormick JJ (2010) Rac1 and Cdc42 are regulators of HRasV12-transformation and angiogenic factors in human fibroblasts. BMC Cancer 10:13
61. Qiu RG, Abo A, McCormick F, Symons M (1997) Cdc42 regulates anchorage-independent growth and is necessary for Ras transformation. Mol Cell Biol 17:3449-3458 (Pubitemid 27215060)
62. Qiu RG, Chen J, Kirn D, McCormick F, Symons M (1995) An essential role for Rac in Ras transformation. Nature 374:457-459
63. Lito P, Mets BD, Kleff S, O'Reilly S, Maher VM, McCormick JJ (2008) Evidence that Sprouty 2 is necessary for sarcoma formation by H-Ras oncogenetransformed human fibroblasts. J of Biol Chem 283: 2002-2009
64. Lito P, Mets BD, Appledorn DM, O'Reilly S, Maher VM, McCormick JJ (2009) Sprouty 2 regulates DNA Damage-induced apoptosis in Ras-transformed human fibroblasts. J Biol Chem 284:848-854
65. Schaaf G, Hamdi M, Wijnenburg D, Lakeman A, Geerts D, Ersteeg R, Kool M (2010) Silencing of SPRY1 Triggers Complete Regression of Rhabdomyosarcoma Tumors Carrying a Mutated RAS. Gene Cancer Res 70:762-771
66. Yigsaw Y, Dartin L, Pierre S, Scholich K, Patel TB (2001) The C terminus of Sprouty is important for modulation of cellular migration and proliferation. J Biol Chem 276:22742-22747
67. Liang P, Averboukh L, Pardee AB (1993) Distribution and cloning of eukaryotic mRNAs by means of differential display: refinements and optimization. Nucleic Acids Res 21:3269-3275 (Pubitemid 23230499)
68. Qing J, Wei D, Maher VM, McCormick JJ (1999) Cloning and characterization of a novel gene encoding a putative transmembrane protein with altered expression in human tumors. Oncogene 18:335-342 (Pubitemid 29060609)
69. Ishii H, Kim DH, Fujita T, Endo Y, Saeki S, Yamamoto TT (1998) cDNA cloning of a new low-density lipoprotein receptor-related protein and mapping of its gene (LRP3) to chromosome bands 19q12-q13. 2. Genomics 51:132-135 (Pubitemid 28373382)
70. Battle MA, Maher VM, McCormick JJ (2003) ST7 is a novel low-density lipoprotein receptor-related protein (LRP) with a cytoplasmic tail that interacts with proteins related to signal transduction pathways. Biochemistry 42:7270-7282 (Pubitemid 36735806)
71. Battle MA, McCormick JJ (2001) Expression of ST7, a novel low-density lipoprotein receptor-related protein (LRP), inhibits tumorigenicity in human fibrosarcomas [unpublished studies]
72. Qing J, Maher VM, Tran H, Argraves WS, Dunstan RW, McCormick JJ (1997) Suppression of anchorageindependent growth and matrigel invasion and delayed tumor formation by elevated expression of fibulin-1D in human fibrosarcoma-derived cell lines. Oncogene 15:2159-2168 (Pubitemid 27493905)